Sign up
Log in
Why Liontown, Newmont, Paladin Energy, and ResMed shares are charging higher today
Share
Listen to the news
A man clenches his fists in excitement as gold coins fall from the sky.

The S&P/ASX 200 Index (ASX: XJO) is having another solid session on Thursday. In afternoon trade, the benchmark index is up 0.65% to 7,973 points.

Four ASX shares that are rising more than most today are listed below. Here's why they are storming higher:

Liontown Resources Ltd (ASX: LTR)

The Liontown Resources share price is up 2% to 57 cents. This follows the release of the lithium miner's quarterly update. Liontown reported production of 95,709 dry metric tonnes (dmt) of spodumene concentrate (up 12%) and the sale of 93,940 dmt across five shipments (up 15%). This led to Liontown's revenue increasing 17% to A$104 million for the period. And with its unit costs down 18% to A$816 (US$512) per tonne, Liontown recorded positive cash flow of A$14 million for the three months.

Newmont Corporation (ASX: NEM)

The Newmont share price is up 3% to $85.02. This follows a rebound in the gold sector and the release of the gold miner's quarterly update. In respect to the latter, Newmont's adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) fell 14% to US$2.6 billion. However, its underlying EBITDA increased by US$307 million thanks to higher net income.

Paladin Energy Ltd (ASX: PDN)

The Paladin Energy share price is up a further 11% to $5.50. Investors have been buying the company's shares this week after it reported the highest level of quarterly uranium production at its Langer Heinrich Mine (LHM) since its restart. It produced 745,484lb U3O8 over the three months, which is up 17% quarter on quarter. This was despite the "one-in-fifty-year rainfall event" that impacted its operations in March. In response to the update, the team at UBS has retained its buy rating and $9.10 price target on the uranium miner's shares.

ResMed Inc. (ASX: RMD)

The ResMed share price is up 7% to $35.63. This has been driven by the release of the sleep disorder treatment company's quarterly update. ResMed reported an 8% increase in revenue to US$1.3 billion. This reflects increased demand for its sleep devices and masks portfolio, as well as solid growth across its Residential Care Software business. In respect to earnings, the company's income from operations increased by 14% to US$426.3 million and its non-GAAP net income rose 11% to US$348.5 million. ResMed's CEO, Mick Farrell, said: "Our positive fiscal year 2025 performance continued in the third quarter, with strong top-line revenue growth, margin expansion, and double-digit EPS growth resulting from solid customer demand for our best-in-class products and software solutions."

The post Why Liontown, Newmont, Paladin Energy, and ResMed shares are charging higher today appeared first on The Motley Fool Australia.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2025

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.